<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1067">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05147259</url>
  </required_header>
  <id_info>
    <org_study_id>HR011408-101</org_study_id>
    <nct_id>NCT05147259</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HR011408 at Two Formulations in Healthy Subject</brief_title>
  <official_title>A Single Center, Randomized, Double-Blind, Single Ascending Dose, Crossover Designed Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HR011408 at Two Formulations in Healthy Subject</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the safety, tolerability and pharmacokinetics of&#xD;
      HR011408 at two formulations in healthy subject.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 29, 2021</start_date>
  <completion_date type="Anticipated">February 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover Assigned to HR011408(formulation A) or HR011408(formulation B)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs)</measure>
    <time_frame>from Day1 to Day15</time_frame>
    <description>The incidence of adverse events will be collected and the safety of HR011408 will be assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>from 0 to 10 hours after dose administration</time_frame>
    <description>Area under the concentration-time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>from 0 to 10 hours after dose administration</time_frame>
    <description>Maximum observed concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed concentration (Tmax)</measure>
    <time_frame>from 0 to 10 hours after dose administration</time_frame>
    <description>Time to maximum observed concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>from 0 to 10 hours after dose administration</time_frame>
    <description>Elimination half-life (t1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to 50% maximum observed concentration (time to 50% Cmax)</measure>
    <time_frame>from 0 to 10 hours after dose administration</time_frame>
    <description>Time to 50% maximum observed concentration (time to 50% Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset of appearance</measure>
    <time_frame>from 0 to 10 hours after dose administration</time_frame>
    <description>First time point after dose administration when concentration reaches lower limit of quantification (LLOQ)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of development of Anti-drug Antibodies (ADAs)</measure>
    <time_frame>from Day1 to Day15 after dose administration</time_frame>
    <description>Incidence of Anti-drug Antibodies (ADAs) will be assessed</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes in Adults</condition>
  <arm_group>
    <arm_group_label>Cohort one: Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort two: Medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort three: high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR011408 injection</intervention_name>
    <description>Drug: HR011408 injection (formulation A), administered subcutaneously. Drug: HR011408 injection (formulation B), administered subcutaneously.</description>
    <arm_group_label>Cohort one: Low dose</arm_group_label>
    <arm_group_label>Cohort three: high dose</arm_group_label>
    <arm_group_label>Cohort two: Medium dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged 18-55 years(both inclusive) at the time of signing informed&#xD;
             consent&#xD;
&#xD;
          2. Body mass index 18.0-26.0kg/m2(both inclusive)&#xD;
&#xD;
          3. Body weight ≥50.0kg(male),≥45.0kg(female)&#xD;
&#xD;
          4. Fasting serum/plasma glucose &lt;6.1mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected of being allergic to any ingredient in the study drug.&#xD;
&#xD;
          2. Participated in any drug or medical device-related clinical trial within 3 months&#xD;
             before screening.&#xD;
&#xD;
          3. Subjects addicted to smoking, or non-smoker who smoked within 48 hours before&#xD;
             administration&#xD;
&#xD;
          4. Donated blood within 1 month before screening; or donated blood ≥400 mL or had blood&#xD;
             loss ≥400 mL during trauma or major surgery within 3 months before screening.&#xD;
&#xD;
          5. Subjects with incompetence or language impairment, who cannot fully understand or&#xD;
             participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sheng Feng, Ph.D.</last_name>
    <phone>+86-0518-82342973</phone>
    <email>Sheng.feng@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yifan Li</last_name>
    <phone>+86-0518-82342973</phone>
    <email>yifan.li@hengrui.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

